Eli Lilly & Co. (LLY) Tops Q2 EPS by 72c; lifts guidance

Eli Lilly & Co. (NYSE: LLY) reported Q2 EPS of $6.31, $0.72 better than the analyst estimate of $5.59. Revenue for the quarter came in at $15.56 billion versus the consensus estimate of $14.67 billion.

GUIDANCE:

Eli Lilly & Co. sees FY2025 EPS of $21.75-$23.00, versus the consensus of $21.98. Eli Lilly & Co. sees FY2025 revenue of $60-62 billion, versus the consensus of $60.09 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.

You May Also Be Interested In

• OneMain (OMF) Reiterated at Market Outperform by Citizens on Updated Estimates
• Jefferies Reinstates Talen Energy (TLN) at Hold
• This digital health stock is ready to re-rate higher: Goldman